New-Onset Catatonia and Delirium in a COVID-Positive Patient

Coronavirus disease (COVID-19) is a strain of coronavirus family, which was initially found in China in late 2019 and subsequently spread to rest of the world. COVID-19 has led to physical and mental health complications since its onset. In addition to the pandemic-associated social stresses, biological complications include direct viral encephalitis, autoimmune-mediated responses, medication side effects, hypoxic brain injury, and delirium, which can collectively cause varied presentations of neuropsychiatric symptoms. Neuropsychiatric complications have been reported in the acute stages of COVID-19 and post-infection period. Here we report our experience treating a patient who initially presented with a severe depressive episode and subsequently developed catatonia and delirium following hospital-acquired COVID-19 infection.

[1]  A. Heidari,et al.  Postinfectious COVID-19 Catatonia: A Report of Two Cases , 2021, Frontiers in Psychiatry.

[2]  Margaret E. Wohlleber,et al.  COVID-19 and Catatonia: A Case Series and Systematic Review of Existing Literature , 2021, Journal of the Academy of Consultation-Liaison Psychiatry.

[3]  S. Kumar,et al.  Neuropsychiatric and Cognitive Sequelae of COVID-19 , 2021, Frontiers in Psychology.

[4]  Ankit Jain,et al.  Posttraumatic Stress Disorder Exacerbation as a Result of Public Masking in Times of COVID-19. , 2020, The primary care companion for CNS disorders.

[5]  A. Ruiz,et al.  Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia , 2020, Frontiers in Aging Neuroscience.

[6]  R. Baweja,et al.  Mental Health Crisis Secondary to COVID-19-Related Stress: A Case Series From a Child and Adolescent Inpatient Unit. , 2020, The primary care companion for CNS disorders.

[7]  David A. Ross,et al.  COVID-19 Catatonia—Would We Even Know? , 2020, Biological Psychiatry.

[8]  F. Motiwala,et al.  Risk of QTc prolongation with Chloroquine/Hyroxychloroquine and Azithromycin treatment for COVID‐19: Quantification and precautions for a busy clinician , 2020, Journal of arrhythmia.

[9]  Z. Mansuri,et al.  Ritonavir/Lopinavir and Its Potential Interactions With Psychiatric Medications: A COVID-19 Perspective. , 2020, The primary care companion for CNS disorders.

[10]  M. K. Zafar,et al.  Remdesivir and Potential Interactions With Psychotropic Medications: A COVID-19 Perspective. , 2020, The primary care companion for CNS disorders.

[11]  Christopher T. Lim,et al.  A Case of Catatonia in a Man With COVID-19 , 2020, Psychosomatics.

[12]  Paolo Fusar-Poli,et al.  Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic , 2020, The Lancet Psychiatry.

[13]  A. Francis,et al.  Catatonia revived: a unique syndrome updated , 2020, International review of psychiatry.

[14]  G. Northoff,et al.  Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[15]  G. Ungvari,et al.  The pharmacological treatment of catatonia: an overview , 2011, European Archives of Psychiatry and Clinical Neuroscience.